Guatemala Medical Device Registration: 20 FAQs on MSPAS Sanitary Registration and Classification (2026)

How to read this article: every conclusion below is taken from the regulatory texts and technical standards currently published on the official website of the Direccion de Regulacion y Control de Productos Farmaceuticos y Afines (DRCPFA) of Guatemala’s Ministerio de Salud Publica y Asistencia Social (MSPAS). The 20 questions and answers that follow cover the core issues of market access in Guatemala.

Part 1: The Regulatory Framework – Getting the Governing Logic Right First

Q1 Does Guatemala have a standalone Medical Device Law?

No. Guatemala has no single device statute. Devices are regulated as productos afines (related products) within the pharmaceutical regulatory framework, and the registration certificate is an Inscripcion Sanitaria (sanitary registration), not the Registro Sanitario used for medicines.

Basis: Article 1 of AG 712-99 sets out the scope of application, covering medicamentos, material de curacion, reactivos de laboratorio para uso diagnostico, and productos y equipo odontologico; Article 4 (Integracion) of NT 37 states that materials and medical-surgical materials are consolidated under Dispositivos Medicos.

Q2 Who is the competent authority?

A three-level structure: MSPAS, then DGRVCS (Direccion General de Regulacion, Vigilancia y Control de la Salud), then DRCPFA (Direccion de Regulacion y Control de Productos Farmaceuticos y Afines). Registration, changes, renewals and import permits are all handled by DRCPFA.

Basis: the header of NT 37, 5th-2016 version, states that it is issued by DGRVCS acting through DRCPFA; Article 2 of AG 712-99 empowers MSPAS to oversee the control of inscripcion sanitaria.

Q3 Which core regulations are currently in force?

• AG 712-99 (17 September 1999), Reglamento para el Control Sanitario de Medicamentos y Productos Afines – the parent-level regulation;
• AG 104-2018 (12 June 2018), which amends AG 712-99, including the definitions in Article 7 and the GMP-related provisions;
• NT 37, 5th-2016 version – the only dedicated device standard, issued on 22 February 2016 and effective upon publication on the official website, repealing the 4th-2015 version (Articles 13 and 14);
• AG 53-2022 – the DGRVCS schedule of technical service fees, and the basis for official fees;
• NT 26, 3rd-2017 version (import permits), NT 36, 06-2023 version (market sampling) and NT 48-2020, 4th version (distributor licences).

Basis: the texts currently listed on the MSPAS official website under Legislacion Vigente (Acuerdos / Normas Tecnicas).

Q4 What counts as a medical device, and how is it separated from a medicine?

Article 3.1 of NT 37: any instrument, apparatus or similar article intended for the diagnosis, prevention, monitoring, treatment, alleviation, replacement or support of disease or injury in humans, including care during pregnancy and childbirth, together with its components, accessories and software.

The dividing line sits after Article 3.1.5: a device does not achieve its principal intended action by chemical means in or on the body, and is not metabolised in the body; if a pharmacological action is assigned to it by virtue of its composition, it must be registered as a medicine; products that can be degraded and absorbed by the body (absorbable sutures, for example) nevertheless remain devices.

Basis: NT 37, Articles 3.1 and 3.1.1-3.1.5.

Part 2: Classification – Why Both the Three-Class and Four-Class Versions Circulating Online Are Wrong

Q5 Which products do not require registration?

Two exemptions (Article 2 of NT 37): first, products used for the disinfection or sterilisation of devices; second, the medical equipment not requiring registration listed in Annex 2 – X-ray machines, dental X-ray units, electrocardiographs, hospital monitors, dental treatment units, periodontal ultrasonic units, autoclaves, hospital beds and linen, crutches, plaster saws and similar items.

Practical note: Annex 2 is a positive list, so anything not listed requires registration. And exemption from registration is not exemption from import permits: imports remain subject to Article 52 of AG 712-99 and to NT 26.

Q6 How many classes does Guatemala use?

Four. The classification dimension is not high, medium or low risk, but a 2 x 2 matrix of site of use against sterility (Article 12 and Annex 1 of NT 37):

Examples given in Annex 1: Class I – examination gloves, tongue depressors, three-piece syringes; Class II – sterile surgical gloves, sterile gauze, sterile dressings; Class III – bone plates, bone screws; Class IV – sterile catheters, sterile surgical sutures, heart valve products.

Practical note: planning on an I-to-III class basis goes straight into the wrong slot in Guatemala. A sterile consumable used internally may be Class II in another country, but here it is Class IV, and both the testing scope and the depth of documentation are entirely different.

Q7 How does classification affect actual cost and timeline?

Only Class I can take the no-analysis route; Classes II to IV must submit sealed samples and obtain a physicochemical or microbiological report from LNS (Laboratorio Nacional de Salud). If the report fails, the registration is automatically revoked and the product must be withdrawn from the market within 15 days.

Basis: NT 37, Annex 1 and the explanatory note at the end of the annex pages; Article 47 of AG 712-99 requires invasive products to be analysed.

Part 3: Applicant Eligibility – Where 90% of Projects Go Wrong

Q8 Can a Chinese manufacturer hold the registration itself?

No. The applicant must be an enterprise legally established in Guatemala and holding a valid Licencia Sanitaria (sanitary licence); the application form must be signed, stamped and fingerprint-marked by a Quimico Farmaceutico (pharmacist) registered in Guatemala.

Basis: NT 37, Article 5.1.13 (copy of the applicant’s sanitary licence) and Article 5.1.2 (pharmacist signature and stamp); AG 712-99, Article 3 (the manufacturer or seller is responsible for holding the licence and keeping the product registration valid) and Articles 71.11, 71.12 and 72 (droguerias and distribuidoras are licensed premises).

Q9 Are an authorised representative and a registration holder the same thing?

No – they are two separate documents. The Poder de Representacion (power of representation) is issued by the manufacturer and notarised and authenticated; it answers who speaks to MSPAS on the manufacturer’s behalf. The Licencia Sanitaria is held by the Guatemalan company; it answers who has the right to import and sell.

The registration certificate names only one titular (holder). If the holder is the distributor, commercial control of the certificate and the import channel both sit with the distributor; changing the holder later requires the formal Cambio de Titular procedure under Article 6.1 of NT 37, with a change application, legal documents, the original certificate or a statement of non-submission, the original packaging or artwork, and proof of payment of the change fee.

Practical note: build an unconditional transfer-of-registration clause on the manufacturer’s request into both the power of representation and the distribution agreement up front. That costs far less than running the change procedure later.

Part 4: Documentation and Compliance Detail

Q10 What must be submitted for a first registration?

Article 5.1 of NT 37 lists 13 items, and even the binding method is written into the regulation: a natural-colour ring binder, using the current version of form F-AS-f-08. The core list:

• Proof of payment of the registration fee, including the sanitary surveillance fee;
• Form F-AS-f-08, signed and stamped by the pharmacist;
• Finished-product specifications in Spanish;
• Product description in Spanish;
• Certificate of free sale issued by the health authority of the country of origin;
• GMP certificate or certificate of an equivalent sanitary standard;
• Notarised copy of the manufacturer’s power of representation;
• Analytical methods, where applicable;
• Certificate of analysis issued by the manufacturer at the time of release;
• Originals or clear artwork of the primary and secondary packaging (photocopies and over-stickered labels are not accepted);
• Sealed samples, in the quantities specified in the LNS schedule;
• Technical material, catalogue and instructions for use in Spanish;
• Copy of the applicant’s sanitary licence.

Basis: NT 37, Articles 5.1.1-5.1.13.

Q11 How are foreign documents legalised, and who does the translation?

Five hard rules (Article 5.2 of NT 37):

• Originals may be replaced by notarised copies;
• Documents must be valid on the date of submission;
• Documents issued abroad must complete the statutory authentication formalities before they are valid in Guatemala – Guatemala has applied the Hague Apostille Convention since 18 September 2017, so in practice an apostille is used;
• Documents not in Spanish must be translated by a sworn translator authorised in Guatemala; translations produced abroad are not accepted;
• For documents that carry no expiry date, a maximum of 2 years from the date of issue is accepted.

Basis: NT 37, Articles 5.2.1-5.2.6; official notices of the Hague Conference on Private International Law (HCCH).

Q12 We already hold FDA 510(k), CE and NMPA certificates – can that waive registration or speed it up?

It cannot waive registration, but it is a substantive plus. Article 47 of AG 712-99 requires materials and medical-surgical materials to be manufactured to internationally recognised standards such as those of the FDA and the European Union; Article 5.1.6 of NT 37 accepts a GMP certificate or a certificate of an equivalent sanitary standard.

The reverse risk deserves more attention: if the GMP certificate, the certificate of free sale or the power of representation expires, that is in itself a statutory ground for refusing or revoking registration (Articles 10.3 and 11 of NT 37).

One point also needs clearing up: Guatemala has no Central American Technical Regulation (RTCA) for medical devices. The RTCA section of the MSPAS website lists regional regulations covering only medicines, natural products, cosmetics and pesticides; devices are governed by the national NT 37. A proposal sold on the strength of compliance with a device RTCA has no anchor in the regulation.

Basis: Article 47 of AG 712-99; Articles 5.1.6, 10.3 and 11 of NT 37; the R.T.C.A. listing on the MSPAS official website under Legislacion Vigente.

Q13 What are the hard labelling requirements?

Secondary packaging: product name; directions for use and warnings (for imported products this field must be in Spanish); quantity or contents; batch number; registration number; manufacturer name and country of manufacture; expiry date; the word Esteril (sterile) where applicable; dimensions; and storage temperature.

Primary packaging: product name, batch number, expiry date and registration number. Supplementary labels or instructions for use may carry other information, but it must be truthful, verifiable and not misleading to the consumer.

Basis: NT 37, Articles 7.1.1-7.1.10 and 7.2.1-7.2.6, together with the notes following those articles.

Part 5: Cost and Time – Two Popular Claims Corrected

Q14 What are the official fees, exactly?

Far below the USD 700 to 5,000 range circulating in the market. Under the schedule to Article 5 of AG 53-2022:

The real cost is not in the official fees but in writing the Spanish technical file, sworn translation, notarisation and apostille, international shipment of sealed samples, and the time consumed by correction rounds. If the rates are adjusted later, the MSPAS publication prevails.

Basis: the schedule to Article 5 of AG 53-2022, published in Diario de Centro America, issue No. 26 of 28 February 2022.

Q15 How long does it take to obtain the certificate, and is there a statutory deadline?

There is no statutory review deadline. Neither NT 37 nor the official process document F-AA-p-01 sets any deadline for MSPAS to complete its review. The official process runs: pay the fee and obtain receipt 63-A2, file with DRCPFA, the system accepts the dossier and issues a SIAD, documents and samples are reviewed, the file is referred to LNS where analysis is required, the analysis report is issued, the Certificacion is issued, and the certificate is collected at the ground-floor window. Where documents do not match, a nota de reparo (correction notice) is issued; where the analysis fails, the application is cancelled outright (baja).

Any promise of approval in 2 to 3 weeks, or of 6 to 12 months, therefore has no regulatory basis. Only three variables are within your control: getting the documents right the first time, the laboratory’s scheduling, and the speed of your response to correction notices.

Basis: DRCPFA official process document F-AA-p-01, Procedure for the receipt and assessment of sanitary registration dossiers for related products.

Part 6: Certificate Lifecycle

Q16 How long is the certificate valid, where is the renewal window, and what happens if it lapses?

Five years from the date of grant (Article 8). Renewal must be filed before expiry, with form F-AS-f-08, a renewal application signed and stamped by the pharmacist, a notarised sworn declaration by the legal representative confirming that the original approval conditions are unchanged, a copy of the original certificate, and proof of payment of the renewal fee (Articles 9.1-9.4).

Once expired, the full dossier must be repeated as a new registration (final paragraph of Article 9). Article 49 of AG 712-99 is even more explicit: where renewal documents are not filed before expiry, DRCPFA treats the registration as cancelled.

Practical note: set the renewal start point six months before expiry, and have the holder maintain a four-item expiry register covering the GMP certificate, the certificate of free sale, the power of representation and the sanitary licence. Any one of them lapsing triggers refusal under Article 10.3 or revocation under Article 11.

Q17 What if we change the holder, the manufacturing site or the packaging?

All of these go through form F-AS-f-10, Application for the update of the sanitary registration of related products, with legal documents, the original certificate or a statement of non-submission, the original packaging or artwork, and proof of payment, filed according to the type of change (Article 6). The change types already defined are: change of holder (6.1), change of manufacturer or holder name (6.2), change of product name (6.3), change of legal representative in Guatemala (6.6), change of distributor (6.7), change of responsible pharmacist (6.8), cancellation (6.9), change of primary packaging (6.10), change of packaging or presentation (6.11), and addition of an alternate manufacturing site (6.12).

Item 6.12 is the most commonly misunderstood. Where the same manufacturer produces at a different site and the formulation, presentation and labelling are unchanged, the same registration number is retained and only a change application is filed, with a sworn declaration by the legal representative, proof of payment, the original packaging artwork, the original certificate or an explanation, and a manufacturing assurance letter issued by the health authority (GMP, ISO, FDA, DGKC, IFCC or similar). This is a change, not a new registration – but a false declaration falls squarely within the forged-or-altered-documents revocation ground in Article 11.2.

Basis: NT 37, Articles 6.1-6.12 and Article 11.2.

Part 7: Refusal, Revocation and Post-Market

Q18 On what grounds can an application be refused or a registration revoked?

Refusal of registration (Article 10): failure to meet the requirements of Article 5; presence of materials prohibited or restricted in devices; an expired GMP certificate, manufacturing authorisation, certificate of free sale or power of representation; or the product is not a medical device.

Revocation of registration (Article 11): the product is unsafe under the labelled conditions; the registration documents are forged or altered; failure to comply with the manufacturer’s established quality control; or sale outside the approved conditions. Article 51 of AG 712-99 adds seven parallel grounds. Separately, a failed LNS analysis leads to automatic revocation of the registration and withdrawal from the market within 15 days.

Basis: NT 37, Articles 10 and 11; Article 51 of AG 712-99; the explanatory note at the end of the annex pages of NT 37.

Q19 What continuing obligations apply to import and to the post-market period?

• Batch-by-batch import permits: under Article 52 of AG 712-99 and NT 26, 3rd-2017 version, using form F-SI-r-01 and its attachments, now declared through the MSPAS import platform;
• Market surveillance: DRCPFA may take samples and retain them, under NT 36, 06-2023 version;
• Advertising and promotion: advertising of related products requires authorisation (NT 53-2020);
• Tecnovigilancia (device vigilance): the current NT 37 contains no standalone clause or deadline for reporting device adverse events, and this must be stated plainly, because any claim of a 72-hour or 10-day reporting rule finds no basis in Guatemala’s current regulation. The obligation is at present enforced indirectly through the Article 11 revocation grounds and through NT 36 market surveillance; it will only be made explicit in the new regulation.

Basis: Article 52 of AG 712-99; NT 26, NT 36 and NT 53-2020; the Importacion section of the MSPAS official website (F-SI-r-01).

Q20 What should we watch over the next 12 to 24 months?

First, the draft new regulation. MSPAS has held a public consultation on the draft Reglamento para la Regulacion y Control Sanitario de Medicamentos y Productos Afines (13 February to 14 April 2026, extended to 14 May). The draft writes tecnovigilancia into the remit of MSPAS for the first time, adds a definition of device-related problems (covering design and manufacturing defects, misuse, lack of maintenance and even cyber attacks), creates medical device laboratory as a separate premises category, and in Article 140.11 requires IVD and device advertising to include educational information on use and disposal.

Second, full digitalisation. AM 263-2025 is clearing the backlog of applications inherited from the paper era; the online platform is progressively replacing physical filing in natural-colour ring binders.

Third, the regional mutual recognition gap. There is still no RTCA and no mutual recognition resolution for devices, whereas cosmetics and natural products already have recognition mechanisms. Delivering one dossier across several countries in devices still depends on each company’s own capability, not on a regional agreement.

Basis: the Normas Tecnicas en Construccion section of the MSPAS official website (draft download=383); Acuerdo Ministerial 263-2025; the R.T.C.A. listing.

Why these details decide whether a project succeeds

Registration in Guatemala is not, at bottom, a matter of filling in a form. It is three workstreams that have to run at the same time:

• Classification determination – one class wrong and the testing scope, the timeline and the cost are all wrong;
• Entity structure – the legal relationship among the holder, the power of representation and the sanitary licence determines who ultimately controls the certificate;
• Document validity management – GMP certificate, certificate of free sale, power of representation, sworn translation and apostille: any one of them lapsing triggers refusal or revocation.

Annex: list of regulatory sources cited in this article

• AG 712-99, Reglamento para el Control Sanitario de Medicamentos y Productos Afines – Articles 1, 2, 3, 44, 47, 49, 51, 52, 71 and 72
• AG 104-2018 (amending AG 712-99) – Article 7 definitions and related provisions
• NT 37, 5th-2016 version, Sanitary Registration of Medical Devices – Articles 2 to 14, Annexes 1 and 2
• AG 53-2022, Fee Schedule – schedule to Article 5, items IA-1/2/3, ARISMQ-1/2 and ARSPA-1/2 (DCA 28 February 2022)
• NT 26, 3rd-2017 version (import permits); NT 36, 06-2023 version (market surveillance sampling); NT 48-2020, 4th version (distributors); NT 53-2020 (advertising)
• Draft new regulation (Borrador en revision) – Articles 3, 11.48, 13, 60, 64 and 140.11
• Hague Convention Abolishing the Requirement of Legalisation for Foreign Public Documents – in force for Guatemala since 18 September 2017 (official HCCH notice)

Disclaimer: This article is based on texts published on the MSPAS official website as of 26 October 2026. Where regulations or fee rates are updated, the latest publication by MSPAS or DRCPFA prevails; for the classification and documentation requirements of a specific project, confirm in writing with DRCPFA before submission. This article does not constitute legal advice.